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Cancer is a multifactorial disorder, in which genetic aberrations play a major role. Indeed, cancer 
arise and progress due genomic aberration involving cell cycle control and DNA damage repair, 
which result in uncontrolled cell proliferation[1,2]. 
The majority of cancers are sporadic, and are due to acquired genomic aberration due to a combination 
of stochastic reasons, environmental exposures, there is a subset of cancers arise in familial contexts. 
Familial cancers are cancers that occur in multiple members of a family with a frequency higher than 
that expected by the incidence in the general population, and these families are frequently 
characterized by multiple cancers in one individual and/or early age of onset. Familial cancers may 
occur due to an underlying oncogenic germline DNA alteration, shared exposure to environmental 
risk factors, or both. Inherited pathogenic variants in a single gene characterize most hereditary cancer 
syndromes, which are often due to high-penetrance genes and in which cancer risk is transmitted with 
an autosomic dominant pattern of inheritance. 
 
 
DNA DAMAGE RESPONSE AND CANCER PREDISPOSITION 
DNA damage response (DDR) is composed by multiple pathways which lead to DNA repair or, if 
not possible, to apoptosis or cellular senescence upon single or double strand DNA breaks caused by 
oncogene induced replication stress or carcinogenic agents such as ultraviolet and ionizing radiations, 
reactive oxygen species (ROS), alkylating agents. Acquired dysregulation of one or more DDR 
pathways can lead to genomic instability, one of the hallmarks of cancer[2,3]. 
 
Moreover, several cancer predisposition syndromes have been linked to germline anomalies in the 
DDR pathways[4]. For instance, germline loss-of-function in the homologous recombination repair 
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(HRR) genes BRCA1 and BRCA2 underlie the hereditary breast-ovarian cancer predisposition 
syndrome (HBOC)[5]. Moreover, pathogenic variants in BAP1, a gene encoding for a deubiquitinase 
that interacts with BRCA1, are responsible of a rare multi-cancer predisposition syndrome. Pathogenic 
variants in the mismatch repair genes MSH2 and MLH1 cause Lynch syndrome, a hereditary 
syndrome characterized by increased susceptibility to colorectal and other gastrointestinal cancers, 
as well as malignancies of the ovary, urinary tract, brain and skin[6]. Among genes implicated in non-
homologous end joinining (NHEJ) are TP53, whose germline variants cause Li-Fraumeni syndrome 






PART I: ATM AND MELANOMA 
 
GERMLINE MULTI-GENE PANEL SEQUENCING IN MELANOMA AND RELATED 
CANCERS 
Our Cancer Genetics group’s research is focused mainly on susceptibility to melanoma, as well as 
cancers included in the spectrum of hereditary multi-tumor syndromes that include melanoma in their 
spectrum. 
Melanoma is the most frequently lethal form of skin cancer, and its incidence is increasing in 
countries with a high prevalence of light-skinned individuals. Most melanoma cases are sporadic, and 
the main predisposing causes are phototype and environmental risk factors, in particular light 
complexion combined with exposure to ultraviolet radiation. 
However, up to 5-15% of melanomas arise in individuals belonging to melanoma-prone families or 
melanoma-related multi-cancer syndromes. The gene most frequently responsible for melanoma 
predisposition is CDKN2A, found in 20 to 40% of familial melanoma patients, whereas a small 
(<10%, but still to be clearly defined) proportion of familial patients carry a variant in other melanoma 
predisposition genes, namely BAP1, POT1, MITF, ACD. However, in more than half of high-risk 
melanoma patients, an underlying genetic cause cannot be determined. 
In the last three decades, researchers’ efforts coupled with a progressive improvement of DNA 
sequencing methods led to the discovery and validation of several melanoma predisposition genes, 
and additional candidate predisposition genes are currently being studied (Figure 1). However, 
despite these scientific advances, only part of melanoma heritability can currently be explained by an 
inherited pathogenic variant in a known melanoma predisposition gene. It is possible that additional 
high penetrance genes yet to be discovered contribute to the risk of melanoma. It is more likely 
however that, at least in part, the unexplained heritability could be due to inheritance of variants in 
low to intermediate penetrance genes, which are more difficult to identify due to the lack of complete 
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co-segregation with the disease. Moreover, a variable combination of multiple low-risk alleles and/or 
their interaction with the environment could play a role in melanoma development (Figure 2). 
  
In an effort to to determine whether multi-gene panel testing could lead to an increased mutational 
yeld of known melanoma-predisposition genes, and identify novel melanoma-predisposition genes to 
tackle the issue of missing heritability, our research group performed germline genetic testing on 
cohort of 273  CDKN2A/CDK4 negative malignant melanoma index patients enrolled at multiple 
Italian centers and considered high-risk based on current criteria[9], using an in-house custom panel 
which included POT1, BAP1, MITF (for diagnostic purposes) and the novel candidate melanoma 
susceptibility genes TERT, ACD, TERF2IP, MC1R. In addition, ATM and PALB2, candidate 
pancreatic cancer susceptibility genes, were included in our panel due to the presence of 
CDKN2A/CDK4 negative families prone to both melanoma and pancreatic cancer. 
 
This study showed that panel testing proves to be advantageous in the clinical practice, as it provided 
an increase of 6% of the mutational yeld in the diagnostic setting compared to genotyping of CDKN2A 
and CDK4 alone. However, an even more interesting result derived from the assessment on novel 
candidate predisposition genes, as ATM pathogenic variants were found in 6 out of the 273 patients 




GERMLINE ATM VARIANTS PREDISPOSE TO CUTANEOUS MELANOMA 
 
BACKGROUND AND RATIONALE 
The Ataxia-Telangiectasia mutated (ATM) gene was firstly identified by linkage analysis and 
positional cloning[10]. ATM[1q22.3] is a 146619 nucleotides gene, which encodes for a 370-kDa 
serine-threonine kinase protein composed of 3055 amino acids[11].  
 
ATM is a serine/threonine kinase belonging to the PI3/PI4-kinase family protein that plays a key role 
in genome stability, being part of several cell cycle pathways involved in DNA damage response. In 
particular, ATM is activated upon DNA double strand breaks caused by ionizing radiations, ultraviolet 
radiation and oxidative stress (ROS), and is involved in non-homologous end join, among other 
functions (Figure 3). Indeed, null ATM cells have a high rate of chromosomal aberrations, and show 
lack of DNA damage repair following exposure to ionizing radiations. 
 
Homozygous loss-of-function (LOF) ATM variants cause Ataxia-Telangiectasia (AT), also known as 
Louis-Bar Syndrome, an autosomal recessive syndrome characterized by progressive cerebellar 
degeneration, ocular telangiectasias, immunodeficiency and radiosensitivity[7]. Moreover, 
hematologic malignancies and solid cancers have been found in association with AT, such as breast 
cancer, gastric cancer and pancreatic cancer[12]. 
 
Following the detection of an increased incidence of cancer, especially breast cancer in heterozygous 
parents of AT patients, epidemiological studies showed that truncating ATM variants, as well as 
specific missense variants moderately increases the risk of breast cancer. However, the heterogeneity 
of risk magnitude across different cohort studies, as well as the variability of familial co-segregation 
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for different types of variant in the same study cohort[13]. suggests that different ATM variants may 
confer cancer risk with different penetrance.  
 
In addition to breast cancer, there have been several reports of ATM association with other cancers. 
For instance, ATM pathogenic and likely pathogenic variants are enriched in familial pancreatic 
cancer, suggesting that ATM is a pancreatic cancer predisposition gene[14]. Moreover, ATM has been 
implicated in gastric cancer and prostate cancer [15,16], suggesting that the real extent of ATM tumor 
spectrum is likely broader. 
 
Even in cancers for which ATM link has been established, such as breast cancer, effects on clinical 
practice are heterogeneous in different countries, ranging from annual mammographic screening from 
the age of 40 in the USA/Canada/GB, to the choice of not reporting ATM results from breast-ovarian 
cancer syndrome diagnostic multi-gene panels in France[17–19]. 
 
In 2008, a population study found that a specific ATM common variant, S49C, was more frequent in 
melanoma patients compared to the general population[20]. Moreover, in a recent Genome-wide 
association study (GWAS) carried out by the GenoMel consortium, two variants in the ATM gene 
were associated with melanoma[21,22]. Conversely, a study conducted on melanoma-prone families 
found specific ATM variants in a subset of families, but the global burden test on rare variants showed 
no relationship between ATM and melanoma[23].  
 
AIM OF THE STUDY 
Based on our preliminary findings on ATM pathogenic variants in cutaneous melanoma mentioned in 
the previous chapter, we started and coordinated a multi-centric study with the collaboration of the 




PATIENTS AND METHODS 
Study datasets 
From 10 countries of the GenoMel and MelaNostrum consortia across Europe, the United States and 
Australia, we retrospectively collected information on germline ATM status of 1936 cutaneous 
melanoma cases, either probands of melanoma-prone families, apparently sporadic multiple primary 
melanoma cases, or sporadic melanoma cases belonging to case-control study cohorts. ATM 
genotyping was performed via panel, exome or whole genome sequencing at each recruiting centers. 
 
The Genome Aggregation Database (GnomAD), version 2.1, consists of 125748 exomes and 15708 
genomes from 141456 germline DNA samples belonging to individuals enrolled in disease-oriented 
and population case-control studies. Considering that, unlike the GnomAD database, our study cohort 
includes cases enrolled in countries with predominantly non-Finnish European ancestry, we only 
analyzed the GnomAD Non-Finnish European (NFE) subset, which consists of 64603 individuals 
(56885 exomes and 7718 genomes).  
 
Variants selection 
Out of all ATM variants found in our study cohort, the GnomAD cohort or both, nonsense, frameshift, 
splice acceptor and splice donor variants were considered LOF and included in this study.  
Filtering of missense variants was done according to a frequency criterion. Considering that AT 
prevalence worldwide ranges from 1:40000 to 1:100000[24], the estimated allele frequency of AT 
heterozygotes is 0.002-0.005. Therefore, all missense variants with an AF above 0.005 were 
considered likely benign and excluded from this study. Moreover, missense variants found 
homozygous in more than two GnomAD subjects or whose annotation was considered unreliable in 




Prior to assess whether the frequency of ATM variants differed between the GenoMEL cohort and the 
GnomAD cohort, we grouped all LOF variants together and considered them as a single variable, and 
we performed the same grouping on VUS. 
We then compared the (AF) of selected ATM variants in our cohort and in GnomAD non-Finnish 
Europeans (NFE) using Fisher’s exact test.  





Our study cohort consisted of 1936 cases (941 apparently sporadic from case-control cohorts, 261   
apparently sporadic MPM, and 734 probands of melanoma-prone families).  After filtering, we 
included 1006 unique ATM variants, 158 LOF (15 found in the Genomel db, 140 in GnomAD db, 3 
in both) and 848 unique VUS (42 found in the Genomel db, 731 in GnomAD db, 75 in both). 
In our study cohort we found 19 LOF alleles in 10 familial, three MPM cases, and six sporadic SPM 
cases. Moreover, 193 VUS alleles were found in 136 familial, 22 sporadic MPM and 35 sporadic 
SPM cases. The NFE subset of the GnomAD cohort consists of 64603 individuals, for a total allele 
count of 129206. In this dataset, 4468 alleles had an ATM variant, 223 LOF and 4245 VUS. 
Overall, ATM variants were more represented in our study cohort then in the GnomAD NFE cohort 
(AF 0.05475207 and 0.03458044, OR= 1.6, CI=1.39 - 1.85, p= 7.358e-10).  The highest difference 
was observed for LOF variants (AF 0.005 and 0.002, OR=2.68, CI=1.59-4.29, p=0.0002), especially 




VUS showed a similar, albeit smaller, association, both when considering all cases (AF 0.05 and 
0.033, OR=1.53, CI=1.32-1.78, p=7.947e-08) and the familial/MPM subset (AF 0.07 and 0.033, 
OR=2.22, CI=1.87-2.61, p< 2.2e-16). 
 
ATM genotyping on all affected family members was only available for four probands. Of these, two 
showed complete co-segregation of the variant with melanoma. One family showed partial co-
segregation, whereas in another family only one out of six affected members had the variant.  
Family 11 showed no co-segregation, as only one of three analyzed affected family members had the 
variant; however, no information is available of four additional family members, who had melanoma 
but were not genotyped for ATM (Table 3). 
 
Of all probands with LOF variants, three individuals were also diagnosed with a non-melanoma 
cancer: one had CLL, another had endometrial cancer, whereas a third individual had a diagnosis of 
pancreatic cancer after being diagnosed with melanoma. Non-melanoma ATM-related tumors were 
found in a subset of families: patient 18 had a sister with breast cancer, whereas the mother of patient 
17 was diagnosed with pancreatic cancer. Two more probands, patients 14 and 19, had a second-
degree relative diagnosed with pancreatic cancer; in one case, however, the relative was more than 
80 years old at the time of diagnosis 
 
 
DISCUSSION AND CONCLUSION 
Despite the technological advances that have occurred during the last decades that led to multiple 
discoveries in the study of the human genome and cancer, several questions are still partially 
unanswered. For instance, the majority of heritability of melanoma cannot be explained by germline 
pathogenic variants in a single established predisposition gene and, on the other hand, an increased 
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prevalence of melanoma cases is being found in known familial cancer syndromes for which an 
association with melanoma was not previously established.  
 
An example is ATM, an intermediate breast cancer susceptibility gene that is also a melanoma GWAS 
hit and may be implicated in melanoma susceptibility. However, ATM is a long gene, with a high 
probability of genomic variation due to stochastic reason. Moreover, epidemiological studies on 
breast cancer cohorts show that ATM it confers cancer risk with an intermediate penetrance with 
incomplete co-segregation in families. Considering that the penetrance for melanoma may be 
analogous or even lower than that of breast cancer, collecting information on pedigrees large enough 
to investigate cancer predisposition is a challenge. An additional level of uncertainty is presented by 
the possibility that different types of variants may confer variable cancer risk, which can be 
hypothesized based on prior knowledge deriving from studies on AT patients and high-risk breast 
cancer patients[13].  
 
However, to our knowledge, this is the first hypothesis-driven study to investigate the presence of 
ATM rare variants in a large international multicentric melanoma cohort. Here, we demonstrate that 
ATM pathogenic variants are more frequent in melanoma patients compared to that in the GnomAD 
database, suggesting that ATM may be a melanoma predisposition gene. Indeed, the association with 
melanoma reached its maximum in familial cases, and the analysis of available pedigrees showed co-
segregation with melanoma in a subset of these families. VUS association with melanoma was 
weaker, albeit present, than that of LOF variants. A possible explanation is that, as for AT, missense 
variants confer a lower risk compared to truncating variants. However, at least in part, an intragroup 
heterogeneity in terms of pathogenicity might have affected our results. Indeed, although we only 
included among VUS rare missense variants that were not found in homozygous healthy individuals, 
ATM is a long gene with 63 exons and, therefore, here is a high probability that innocuous single 
nucleotide substitutions occur for stochastic reasons. Therefore, a variable amount of non-pathogenic 
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variants in this group might have diluted an association of missense pathogenic variants with 
melanoma. 
Our study design presents some limitations. The unavailability of healthy individuals from the 
majority of the study groups made it impossible to perform a case-control study with in-house 
controls and, therefore, we reverted to comparing our study cases against population controls. Aware 
of the risk of population stratification bias due non-overlapping distribution of ethnic groups, we 
chose as our control group only the GnomAD NFE cohort, as the affected individuals in our study 
cohort either come from European countries excluding Finland, and melanoma patients from USA 
and Australian centers are likely to be composed mainly of individuals of European descent. 
However, even with this adjustment, the possibility of population stratification bias cannot be 
completely excluded. 
In addition to that, although cleared of individuals with severe pediatric conditions and their affected 
relatives, the GnomAD dataset is composed of several studies datasets, it includes cancer cohorts, 
such as the TCGA, and, therefore, the detection of pathogenic ATM variants in this dataset could be 
due, at least in part, to the presence of affected individuals with ATM-induced germline cancer 
predisposition. Therefore, the real association of ATM pathogenic variants with melanoma could be 
actually higher than the one we observed. To avoid the inclusion of TCGA samples, the analysis 
could have been performed on the whole-genome sequencing (WGS) GnomAD subset but, as only a 
minority of our study samples were sequenced by WGS, this option would have increased sequencing 
platforms differences between cases and controls. We also chose not to limit our assessment to the 
GnomAD controls (control groups of case-control studies for common diseases) and non-cancer 
(individuals not ascertained for having a neoplasm) subsets because they are not a guarantee of being 
a cancer-free control group, as controls for diseases other than cancers might have had a cancer 
diagnosis prior or even at the time of enrollment, depending on the study design and the condition(s) 
being studied, such as for instance psychiatric disorders. 
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If confirmed by further studies, our results could provide benefits in the clinical setting. In the era of 
personalized medicine, DNA damage repair genes are promising targets for novel cancer therapies. 
PARP inhibitors, for example, are used for BRCA1/2-positive breast, ovarian and pancreatic 
cancer[25,26] and have been FDA approved in the USA for castration-resistant ATM-deficient 
prostate cancer following a recent clinical trial[27], but recent studies have shown their potential role 
in the treatment of other ATM-deficient cancers[28–30]. 
 
This study is the preliminary part of a broader project aimed at exploring the link between ATM and 
melanoma. In addition to LOF variants, rare missense variants were enriched in our melanoma cohort. 
To gain a clearer picture on ATM impact in melanoma, it will be necessary to carry out pathogenicity 
assessment of rare missense variants through functional testing. Moreover, an assessment of ATM 
penetrance in melanoma will be crucial to determine the potential clinical utility of germline ATM 












Figure 1. Timeline showing the discovery of melanoma risk genes/loci over time. 
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Table 1. Frequency of ATM LOF variants in the GenoMEL cohort and in the GnomAD 
database 
  GenoMel (All) GenoMEL (Fam + MPM) GnomAD NFE 
LOF alleles 19 13 237 
Total alleles 3872 2246 129206 
AF 0.005 0.006 0.002 
OR* (95%CI) 2.68 (1.59-4.29) 3.66 (1.66-5.54)  
p-value 0.0002 0.0004  
OR= odds ratio, CI= confidence interval. *Odds of finding in the GenoMEL cohort compared to the odds 









Table 2.  Frequency of ATM VUS in the GenoMEL cohort and in the GnomAD database 
  GenoMel (All) GenoMEL (Fam + MPM) GnomAD NFE 
VUS alleles 193 158 4268 
Total alleles 3872 2246 129206 
AF  0.05  0.07  0.033 
OR* (95%CI) 1.53 (1.32-1.78) 2.22 (1.87-2.61)  
p-value 7.947e-08 2.2e-16  
OR= odds ratio, CI= confidence interval. *Odds of finding in the GenoMEL cohort compared to the odds 





























Norway MPM 1 1 1 1/1 - c.3244_3245insTG p.H1082fs FS 3 
Norway MPM 2 1 1 1/1 - c.3284+1G>A  Splice 
3 
USA S 3 1 1 1/1 - c.717_720del  FS 
1 
USA S 4 1 1 1/1 - c.902/1G>T  Splice 
1 
USA S 5 1 1 1/1 - c.6227delT  FS 
1 
USA S 6 1 1 1/1 - c.7629+2T>C  Splice 
1 
USA S 7 1 1 1/1 - c.7928/2A>T  Splice 
1 
France F 8 3 1 1/1 - c.8850+2insA(IVS61) Splice 3 
Australia F 9 3 3 3/3 Yes c.1236/2_1236/1insG p.W412fs FS NA 
Australia F 10 6 6 1/6 No c.7878_7882del p.I2629Sfs*24 FS 1 
Australia F 11 3 3 2/3 Partial c.7828_7829del p.R2610Kfs*1 FS 12 
Denmark F 12 7 3 2/3 Partial c.1236/3_1237delinsATTT FS 
 
Australia F 13  
                   
3 3/3 Yes c.1561/1562 p.R521X NS 
 
Italy S 14 1 1 1/1 - c.3275C>A p.Ser1092Ter NS 1 
Italy F 15 2 1 1/2 - c.3576G>A p.Lys1192= Splice 2 
Italy F 16 2 1 1/2 - c.3576G>A p.Lys1192= Splice 1 
Italy F 17 2 1 1/2 - c.4451delT p.Met1484ArgfsTer15 FS 2 
Italy MPM 18 1 1 1/1 - c.5979_5983delTAAAG p.Ser1993ArgfsTer23 FS 
3  (1CMM, 
2UM) 
Italy F 19 2 1 1/2 - c.8319_8323dupTGTCC p.Pro2775LeufsTer33 FS 3 
Table 3. Overview of probands harbouring ATM LOF variants 
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PART II: BAP1-TUMOR PREDISPOSITION SYNDROME AND BREAST CANCER 
 
BAP1 -TUMOR PREDISPOSITION SYNDROME 
The BRCA1 associated protein-1 (BAP1) [3p21.1] is a 9343 bases long gene which encodes for a 
deubiquitinase with tumor suppressor activity. Its name derives from its ability to bind the BRCA1 
RING finger domain[31], and a recent study suggested that BAP1 can regulate BRCA1/ BARD1 
heterodimer activity[32]. Moreover, BAP1 has been shown to interact with a wide array of other 
proteins, and, although the mechanisms by which it exerts its tumor suppressor functions are largely 
unknown, BAP1 is involved in multiple processes, such as DNA damage response and chromatin 
repair, endoplasmic reticulum metabolic stress response, cell cycle regulation, cell growth and 
inflammatory response[33–42]. 
 
BAP1 somatic loss-of-function variants are a common feature of several solid tumors[43–48]. 
Moreover, germline loss-of-function variants in this gene are responsible for the BAP1 Tumor 
Predisposition Syndrome (BAP1-TPDS), a hereditary condition characterized by susceptibility to 
specific types of cancers[49].  Uveal melanoma, malignant mesothelioma, clear cell renal cancer and 
cutaneous melanoma are the most frequent tumors in BAP1-TPDS families, and are therefore 
considered the core tumors of the syndrome[50–54] and, especially in the case of mesothelioma, BAP 
penetrance can be enhanced by the concurrent exposure to environmental carcinogens, such as 
asbestos[55].  Other types of cancer have been reported in families with germline BAP1 pathogenic 
variants[56–66]. However, the BAP1 syndrome is rare as, although its prevalence is not known, it is 






COLLABORATIVE META-ANALYSIS ON BAP1 AND CANCER PREDISPOSITION 
In the last two years, we participated in a meta-analysis coordinated by Prof. Nicholas Hayward of 
QIMR Berghofer Medical Research Institute (Brisbane, QLD, Australia) that included both 106 
published and 75 unpublished families with BAP1 LOF variants, the largest BAP1 study cohort to 
date, and was aimed at identifying the actual tumor spectrum of the BAP1-TPDS, as well as the gene’s 
penetrance for each tumor[68].  
Based on the results of this meta-analysis, the updated numbers on BAP1-TPDS are as follows: 
- The total number of known BAP1 unique germline variants has increased to 140 (104 LOF and 
36 missense); 
- Individuals with BAP1-TPDS-related cancers had a lower age of onset compared to US 
individuals with the same cancer from the Surveillance, Epidemiology and End Result Program 
(SEER) database[69], and the difference was even higher when considering LOF variants only; 
- Uveal and cutaneous melanoma, mesothelioma and renal cell carcinoma are confirmed to be the 
most frequent tumors in the BAP1-TPDS spectrum. However, the spectrum should also include 
nonmelanoma tumors of the skin (especially basal cell carcinoma), meningioma and 
cholangiocarcinoma. 
 
After the meta-analysis, we included additional published and unpublished families in the BAP1 
database of the Oncogenomics Laboratory (QIMR Berghofer, AU) and the BAP1 Interest Group 
(BIG), reaching a total of 373 families. Interestingly, in 181 families with LOF BAP1 variants, 27 




GERMLINE BAP1 VARIANTS IN BREAST CANCER PATIENTS 
 
BACKGROUND AND RATIONALE 
Breast cancer is the second most common cancer in the world, as well as the most commonly 
diagnosed cancer and the leading cause of cancer death among women[70]. Although the majority of 
breast cancers are sporadic, a small proportion of breast cancer arise in cancer-prone families[71]. 
Pathogenic variants in the high-penetrance BRCA1, BRCA2, CDH1, PTEN, TP53 and STK11 genes 
account for no more than 25% of high-risk individuals, whereas less than 3% of breast cancer risk 
can be attributed to intermediate-penetrance genes, namely ATM, PALB2, and CHEK2[72–78]. 
However, in the majority of familial breast cancers, the predisposing cause cannot be identified, and 
although pathogenic variants in other genes such as BRIP1, RAD51C and RAD51D have been found 
in high-risk individuals and families, reports are equivocal, and their role in breast cancer is still 
debated[79–82]. Therefore, researchers are exploring the possibility that novel yet unknown high-
risk predisposition genes, or different combinations of multiple low-penetrance alleles and 
environmental risk factors, might be responsible of breast cancer predisposition in some families.  
 
Recently, somatic biallelic inactivation of the BAP1 gene in breast cancer samples has been reported 
in the COSMIC database[83]. Moreover, it has been suggested that BAP1 loss leads to chromosomal 
instability in breast cancer cells[33]. 
 
The nature of the relationship between breast cancer and the BAP1-TPDS is, however, difficult to 
assess, as studies published so far have provided conflicting results[68,84,85]. Besides, the occasional 
presence of breast cancer in families with BAP1-TPDS could merely reflect random chance, due to 
the high incidence of this tumor type in the general population. Based on these considerations, we 
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performed this study to assess, through the analysis of both published and novel families, whether 
BAP1 plays a role in breast cancer susceptibility.  
 
AIM OF THE STUDY 
To assess whether the BAP1 gene is implicated in breast cancer susceptibility. 
 
PATIENTS AND METHODS 
6088 high risk Breast cancer (familial and/or young) patients, were recruited during Genetic 
counselling at the Parkville Familial Cancer Centre (Melbourne, AU). In addition, a series of 5847 
apparently healthy controls, belonging to the Lifepool cohort[86] was included in the study. Both 
cases and controls, were tested through comprehensive breast cancer panels using Agilent HaloPlex 
technology were negative for BRCA1 and BRCA2 germline pathogenic variants. 
Loss of heterozygosity assessment was performed on available tumor samples using a mouse 
monoclonal antibody raised against amino acids 430–729 of human BAP1 (C-4, Cat. no. sc-28383; 
Santa Cruz, USA) 
 
RESULTS 
Overall, we found 4 LOF variants, in 7 cases and 1 control (Table 3). Moreover, we found 58 missense 
variants in 59 cases (0.9%) and 38 controls (0.6%). One of the missense variant, the c.1735G>A was 
present in 11 cases, all of East Asian origin. 
Tumor samples, which were available for three of the seven cases with LOF variants and for six of  
the 59 cases with missense variants, were evaluated for loss-of heterozygosity through 
Immunohistochemistry. All three samples with the c.783+2T>C splice donor variant showed no 
nuclear expression of the BAP1 protein.  
As for the missense variants, one case with the c.1946G>A (p.Cys649Tyr) showed LOH, whereas a 
second case retained nuclear BAP1 expression. Similarly, the c.944A>C (p.Glu315Ala) was found in 
 27 
two cases, one with and one without LOH. A fifth breast cancer case showed LOH for the c.176G>A 
(p.Arg59Gln) variant, whereas for the sixth case, who had  the c.1547C>T (p.Pro516Leu) variant, the 
analysis failed. 
 
Although the c.783+2T>C is a canonical splice variant, a functional analysis with a minigene assay, 
to confirm that this variant affects splicing is ongoing (no RNA sample from the patient was 
available). Moreover, we plan to perform functional study to assess the potential pathogenicity of the 
two missense variants that showed LOH. 
 
 DISCUSSION 
Molecular links between BAP1 and BRCA1 and the occasional finding of breast cancer individuals 
among relatives of individuals with BAP1-TPDS have led researcher to hypothesize that BAP1 may 
be a breast cancer predisposition gene[60]. However, breast cancer is a high incidence cancer whose 
occurrence may be unrelated to the BAP1-TPDS, in which it hasn’t been found at frequencies higher 
than expected, and LOH assessment of tumor samples from breast cancer relatives of BAP1-TPDS 
individuals is seldom performed, although in one study IHC showed LOH in one individual with 
breast cancer[83]. 
A reason for the fact that the majority of individuals and families with BAP1 do not develop breast 
cancer may be due either the occurrence of different phenotypes depending on different variants, or 
to the influence of genes modifiers of penetrance and/or phenotype. The first of the two hypothesis 
stems from the knowledge that for other genes, such as ATM, there are reports of milder or different 
phenotypes for rare LOF variants and missense variants. However, c.783+2T>C, the only LOF 
variant for which we could assess and demonstrated LOH, has already been found in a family 
satisfying the criteria for BAP1-TPDS (three first degree relatives diagnosed with mesothelioma, 
unpublished data). On the other hand, the hypothesis that unknown modifiers could influence the 
prevalent tumor phenotype in families is intriguing. We already know that, although several cancers 
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have been included in the BAP1-TPDS spectrum, there are BAP1-deficient individuals with only one 
or two prevalent BAP-1 related tumors in the family, which may be due to variants in additional genes 
and/or environmental modifying factors. Interestingly, none of the cases with LOF variants, nor those 
with missense variants showing LOH had a single criteria for the BAP-TPDS. Namely, the only other 
cancer found in a subset of these families, besides breast cancer, was colorectal cancer. 
  
Apart from high-risk and familial cases, breast cancer is a common cancer in the general population 
and, regardless of its possible association with BAP1 in terms of susceptibility, it can occur also by 
chance. Therefore, the introduction of breast cancer in the spectrum of the BAP1-TPDS could 
represent a challenge in terms of assigning a weighted value to breast cancer within the diagnostic 
criteria of the syndrome. Given this major issue, we believe that the relationship between BAP1 and 
breast cancer needs further investigation, in terms of pathogenicity of variants found in relationship 
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 TABLE 3.  Germline BAP1 variants found in breast cancer cases and healthy controls 
cDNA change Protein change Effect of the variant N cases N controls 
c.37+1G>T - splicing 1  0 
c.783+2T>C - splicing 5  0 
c.876_880delCCCGC p.Pro293GlyfsTer12 missense 1  0 
c.1203T>G p.Tyr401Ter missense  0 1 
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PART III: OTHER PROJECTS  
 
 CDKN2A AND SURVIVAL IN CUTANEOUS MELANOMA PATIENTS 
 
CDKN2A is a three-exon gene located on chromosome 9p21.3 encodes for two protein, p16INK4 and 
p14ARF, and is a regulator of cell cycle progression. Although not being a DNA damage repair gene 
itself, CDKN2A expression is essential for the correct functioning of DNA damage response 




BACKGROUND AND RATIONALE 
 
The incidence of malignant melanoma in Italy is rapidly increasing [88,89]. Although most melanoma 
cases are sporadic and linked to interactions between phenotype and environmental risk factors, 6-
12% of all melanoma patients are clustered within melanoma-prone families, up to 40% of which 
harbour inherited germline variants in the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)/p16Ink4 
tumor suppressor gene [9,90,91]. Individuals harbouring CDKN2A pathogenic variants have a 
lifelong increased risk of developing MPM, as well as other cancers, and at a younger age compared 
to their sporadic counterpart[92–94]. In fact, the occurrence of pancreatic cancer in those individuals 
is estimated to be up to 17% [95–100]. 
CDKN2A pathogenic variants are found in up to 2% of individuals diagnosed with melanoma, and 
the prevalence of these variants is 20- 40% in melanoma-prone families depending on the country, 
being inversely associated with local incidence of melanoma [92,101,102]. Moreover, CDKN2A 
penetrance can be modified by several environmental factors, such as tobacco[103,104], and 
molecular factors. Among the latter, Melanocortin 1 Receptor gene (MC1R) variants seem to increase 
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the risk of melanoma, although studies performed on our population have not confirmed, as yet, this 
finding [93,105,106]. 
 
Melanoma prognosis is influenced by several factors, such as  tumor thickness at diagnosis, nodal 
status, ulceration and mitotic rate [107]. Moreover, several studies are investigating gene expression 
signatures and other molecular tools to help estimate melanoma prognosis[108].  
 
Recently, a study conducted on a Swedish cohort showed  that germline mutation positive (MUT+) 
familial melanoma patients had worse prognosis, in terms of survival, compared to germline mutation 
negative (MUT-) and to untested sporadic melanoma patients [109]. In this Swedish study, MUT+ 
and MUT- patients from melanoma-prone families underwent similar follow-up programmes. 
Similarly, CDKN2A pathogenic variants have been associated with worse survival in another Swedish 
study involving individuals affected by multiple primary melanomas (MPM) [110]. 
Our population is among those with the highest incidence of CDKN2A germline pathogenic variants, 
mainly due to the founder effect of the p.G101W variant [91,111–113]. The multidisciplinary 
melanoma group in our hospital provides an intensive follow-up regimen for all affected individuals 
harbouring a CDKN2A pathogenic variant, regardless of family history. Despite the inherited risks of 
multiple melanomas and of other malignancies, no information on the CDKN2A effect on our 
melanoma patients’ prognosis in terms of survival has been available thus far. Based on the above-
mentioned findings, and considering that variants in the same genes can lead to non-identical effects 
in different populations (due to other interfering genetic/environmental factors), we decided to 
investigate the relationship between CDKN2A and survival in our melanoma cohort. 
 
AIM OF THE STUDY 
To assess the impact of CDKN2A gemline variants in an Italian cohort of melanoma patients 
undergoing a mutation-specific follow-up. 
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PATIENTS AND METHODS 
 
Patients characteristics 
Between 2000 and 2015 we enrolled, among all patients diagnosed with melanoma in our hospital, a 
consecutive series of 1239 patients on whom we performed genetic testing for CDKN2A and collected 
and stored clinical and pathological information.  
Part of this cohort consisted of probands of melanoma-prone families and apparently sporadic patients 
with MPM, tested either for diagnostic or research purposes.  Additionally, a series of apparently 
sporadic single melanoma patients, on whom genetic testing was performed for research purposes, 
was included. For 448 patients, molecular and clinical information has previously been described 
[106]. 
Follow-up was carried out according to standard practice of our hospital. Briefly, follow-up of 
CDKN2A mutation positive (MUT+) patients is carried out by our multidisciplinary team every four 
months starting from diagnosis, regardless of familial status, or more frequently if justified by tumor 
stage according to the guidelines of the Italian Association of Medical Oncology (AIOM)[88]. Skin 
examination by a dermatologist is performed every four months. Familial CDKN2A mutation 
negative (MUT-) patients are followed-up at least every 6 months, or more frequently if justified by 
phenotype or tumor stage. Follow up of sporadic MUT- patients is carried out at least every six 
months for five years, and then once a year, according to phenotype and tumor stage. Skin 
examination by a dermatologist is performed every six months for five years, then once a year (or 
every six months even after five years for patient with high-risk phenotype). 
 
Collection of clinical and pathological data 
Clinical information was obtained through a questionnaire, administered by a trained interviewer, and 
included: personal information, phenotype, personal/family history of other melanomas and other 
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tumors as previously described[91,106]. Clinical records and/or local cancer registry data were used 
to collect follow-up information and confirm causes of death. Pathological information included: 
tumor histology and staging according to AJCC’s TNM staging system [114].  
 
Molecular Analysis 
All patients provided a blood sample from which we extracted genomic DNA. Sanger sequencing to 
assess the mutational status of CDKN2A, CDK4 and MC1R were performed as previously described 
[106,115]. 
 
Selection of patients for Survival Analysis 
From our cohort of 1239 patients, we filtered out all patients with incomplete data concerning follow-
up, mutational status, stage, and those with non-cutaneous melanoma. Subsequently, we selected all 
MUT+ patients and grouped them together, regardless of familial status. Moreover, we selected a 
second group of MUT- patients, matched by age and sex, and with similar tumor stage distribution. 
Since our follow-up scheme is the same for both familial and sporadic MUT+ patients, whereas MUT- 
patients’ follow up differs according to familial status, we decided to exclude familial MUT- patients 
from the survival analysis, so to have a higher homogeneity of follow-up within groups. The resulting 
dataset consisted of 305 patients, 106 MUT+ and 199 MUT. 
 
Patient selection workflow is outlined in Figure 6. 
In order to make sure that our results were not affected by events occurred in the time elapsed between 
melanoma diagnosis and the start of the mutation-based follow-up, we also verified whether survival 
analysis results remained consistent when only including incident patients, using the 24 months cut-
off previously used to assess survival in melanoma patients[116]. To obtain this “incident patients-
only” subset, the same selection process was again applied to patients from our melanoma cohort. 
Only patients enrolled within 24 months from melanoma diagnosis were selected, resulting in a total 
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of 199 incident patients matched for age and sex, and with similar of tumor stage distribution, 62 and 
137 of whom were MUT+ and MUT-, respectively. 
Informed consent was signed by all patients prior to enrollment, according to local ethics committee 
approved protocol. 
 
Endpoints and Statistical analyses 
Our endpoints were to investigate whether CDKN2A mutational status is linked to patients’ prognosis 
in terms of overall survival (OS) and melanoma-specific survival (MSS) in our melanoma cohort 
undergoing a mutation-based follow-up. 
When evaluating the difference of a numerical variable between two groups, we performed the Mann-
Whitney U test. To assess the association between two categorical variables, we used the Fisher’s 
exact test. Association between one ordinal and one categorical variable was performed using the 
Kruskal-Wallis test. OS and MSS were calculated with Cox-proportional hazard regression models 
and Kaplan-Meier curves.  
To analyze OS, events were defined as death by any cause. For MSS, only deaths by melanoma were 
considered events, whereas deaths by other causes were censored. Considering that mutation-based 
follow-up started after patients’ enrollment and CDKN2A genetic testing, we calculated follow-up as 
months from inclusion to censoring or death. 
All analyses were two sided, and threshold for statistical significance was set at p=0.05. Statistical 
analyses were performed within the R computational environment [117], using the packages stats, 









Patients Characteristics  
Whole cohort 
Our cohort, after filtering-out 30 patients with either missing information on CDKN2A mutational 
status or variants of uncertain significance (VUS), consisted of 1187 patients, 129 MUT+ and 1058 
MUT-. Patients and tumor characteristics, and corresponding statistics are shown in Table 4. 
Overall, 59/977 apparently sporadic patients (6%) and 70/210 (33%) of familial patients were MUT+. 
Median age was lower in MUT+ patients compared to MUT- (42 and 50 years, respectively, p<0.01). 
Conversely, sex, tumor stage and median Breslow thickness did not differ depending on CDKN2A 
mutational status. As expected, MPM were more frequent among MUT+ patients (p<0.01). 
Moreover, 31/130 (24%) of apparently sporadic patients diagnosed with MPM were MUT+, 
compared to only 28/847 (3%) of apparently sporadic patients with a single melanoma, as shown in 
Table 5.  
Among MUT+ patients there was a higher rate of individuals who had one or more dysplastic nevi, 
and other skin lesion, surgically removed. 
19% of MUT+ patients had been diagnosed with at least one non-melanoma cancer, compared with 
12% of MUT- patients (OR=1.7%, p=0.042).  
The most frequent CDKN2A variant was G101W (97 patients), followed by E27X (13 patients), 
A127P, P48T, R24P (3 patients each), and A36T, A68L, D74Y, F90S (1 patient each). 
The distribution of MC1R variants was similar in MUT+ and MUT- patients, either using the 5-point 
score described by Davies et al.[116] or a dichotomous approach (p>0.7 in both cases, Table 4). 
 
Study dataset 
After patients filtering and matching for age and sex, median age was 43 in MUT+ and 44 in MUT- 
patients (p=0.719). Moreover, 48 (45%) and 95 (48%) patients were male, while 58 (55%) and 104 
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(52%) were female in MUT+ and MUT- groups, respectively (p=0.81). Tumor stage distribution and 
median Breslow thickness remained similar in MUT+ and MUT- patients (both p>0.8), with the 
majority of patients having stage Ia to IIc tumors. Similarly, the distribution of MC1R variants did 
not differ significantly between groups (p>0.7). Median follow-up length was 123 months (CI=43-
182) in MUT+ patients and 105 months (CI=42-154) in MUT- patients. 
As in the main cohort, patients diagnosed with MPM were more frequently MUT+ (42% compared 
to 11% of MUT- patients, OR=5.97, p<0.01). CDKN2A pathogenic variants were also associated with 
removal of one or more dysplastic nevi (OR=2.25, p=0.026), especially when only considering 
dysplastic nevi removed after genetic testing for CDKN2A (OR=3.06, p=0.023). 
In line with previous reports, the MUT+ had a higher rate of individuals diagnosed with non-
melanoma cancers compared to MUT- (17% vs 9%), albeit this difference was not significant 
(OR=2.08, p=0.054). 
Descriptive statistics performed on the study dataset is shown in Table 6. 
 
Survival Analysis 
Overall event rate was 17% in both MUT+ and matched MUT- patients, whereas deaths by melanoma 
were 10.8% and 7.8% among MUT+ and MUT- patients, respectively.  
As shown in Figure 7a, we did not detect differences in OS between MUT+ and MUT- patients, as 
confirmed by a Cox-proportional Hazard Regression Model: Hazard Ratio (HR)=0.85, p=0.592, 
CI=0.48-1.52. Similarly, MSS did not differ depending on CDKN2A mutational status, as shown in 
Figure 7b (HR=0.86CI= 0.38-1.95, p=0.718,). 
To verify survival in an even more “follow-up-homogeneous” setting, we then performed the analyses 
in the “incident patients-only” subset, obtaining overlapping results both for OS (HR=0.64 CI= 0.28-
1.45, p=0.282,) and MSS (HR=1.87, CI=0.39- 2.95, p=0.9). Kaplan-Meier curves along with Log-






Our study shows that CDKN2A mutational status does not negatively affect survival in our melanoma 
cohort. Both OS and MSS did not vary according to CDKN2A mutational status, when known 
confounding variables such age, sex, and tumor stage were similar in MUT+ and MUT- patients.  
Interestingly, our results are not in line with the previously described Swedish study, in which familial 
CDKN2A MUT+ patients had worse survival compared to familial MUT- and sporadic patients [109]. 
It is possible that intrinsic population differences may modulate CDKN2A impact. Indeed, although 
MUT+ and MUT- had a comparable distribution of MC1R variants which have been suggested to 
affect survival[116], we cannot rule out the possibility that somatic/germline variants in other genes 
may have had a protective effect on survival in our study cohort.  
Moreover, survival according to CDKN2A variants in different regions might be modulated by an 
asymmetric distribution of non-genetic risk factors. For instance, it is not known yet whether different 
environmental exposures can influence prognosis in MUT+ individuals. 
A third hypothesis is that intensive clinical surveillance may modulate survival in this high-risk 
population, possibly by counteracting negative effects on survival due to the CDKN2A variant itself. 
In fact, the impact of follow-up intensity on survival according to CDKN2A pathogenic variants is 
currently unknown, and it must be kept in mind that the Swedish study was performed on patients 
who underwent a familial melanoma-specific follow-up whereas our hospital adopts a different 
strategy.  Considering the high CDKN2A mutation rate of our population, we have a considerable 
number of apparently sporadic MUT+ patients whose risk deriving from their first melanoma, as well 
as the risk of developing MPM, may not be inferior to that of their familial counterpart [91,111–113]. 
Indeed, we observed a 24% CDKN2A mutation rate in apparently sporadic patients who had MPM, 
compared to 3% in those who only had one melanoma diagnosis.  Considering that close surveillance 
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in high-risk groups such as MUT+ is encouraged by multiple evidence in order to improve early 
diagnosis[9,120,121], our hospital offers an  intensive follow-up to MUT+ individuals. 
 
 
The proportion of individuals who had one or more dysplastic nevi removed was higher among 
MUT+ patients, especially when only considering dysplastic nevi removed after DNA testing. This 
difference was even higher when we restricted the analysis to incident patients. Hence, it is possible 
that intensive follow-up resulting in detection and removal of dysplastic lesions reduced the 
occurrence of metachronous melanomas in MUT+ patients. 
Unfortunately, due to the retrospective nature of our cohort, our data on individual patients’ follow-
up is incomplete and thus we cannot compare median follow-up intervals between MUT+ and MUT, 
even though the higher rate of dysplastic nevi removal after DNA testing may be an indirect indicator 
of a more intensive follow-up in the MUT+ group. Therefore, although follow-up may be involved 
in the non-inferior survival of MUT+, this hypothesis needs to be verified prospectively. 
Another limitation is that only probands of familial melanoma patients were included in our cohort: 
although providing the advantage of having independent observations, this lowered the size of our 
familial subset. Likely for this reason, we did not have enough data to analyze both the association 
of CDKN2A with the occurrence of specific cancers (such as pancreatic) and survival by non-
melanoma cancers. The downsizing of our cohort needed to obtain an accurate dataset for survival 
analysis also prevented us from carrying out further analyses, such as direct comparison between 
MUT+ and MUT- among familial-only patients.  In addition, the majority of patients in both groups 
were still alive at censoring time. Due to the above-mentioned exclusion of affected family members 
of the probands, along with the fact that the majority of our cohort’s patients had Stage I and II 
melanomas, it is possible that the number of deaths we observed was insufficient to detect an effect 
of CDKN2A on survival. 
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In conclusion, despite recent findings, CDKN2A mutational status is not associated with survival in 
our cohort. Whereas several potential modifiers could be implicated in region-specific differences 
concerning CDKN2A-related melanoma survival, further studies are needed to verify these 
hypotheses. 
This study, now published in the Journal of the American Academy of Dermatology (JAAD)[122], 
is part of an ongoing project aimed at unraveling the relationship between CDKN2A, disease 
characteristics and survival. Upon the enrollment of a higher number of patients, we plan to compare 
MUT+ and MUT- familial melanoma patients, and to analyze mortality by melanoma and other 
cancers in different subgroups, also extending the analysis to affected family members of the already 
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Sporadic MUT+ (N=43)
Study dataset  (N= 305)  Matched - Age, Sex (N=199)All (N=106)
N= 1187
Missing mutational status/VUS (N= 52)





Whole cohort. Clinical, pathological and molecular characteristics   
N MUT WT OR Lower CI Upper CI T  H         p 





73 (0.57) 573 (0.54) 
      
Age median 
(IQR) 
1187 42 (32-53) 50 (39-63) 




Stage IS 1027 5 (0.02) 121 (0.06) 
    
2.06 0.151  
I 
 
71 (0.27) 537 (0.26) 




20 (0.08) 171 (0.08) 




7 (0.03) 56 (0.03) 




5 (0.02) 34 (0.02) 
      
Familial fam 1187 70 (0.54) 140 (0.13) 




59 (0.46) 918 (7.12) 
      
N. of 
Melanomas  
cum 1185   












61 (0.47) 114 (0.11) 
      
Breslow median 
(IQR) 
1133 0.9 (0.4-1.9) 0.84 (0.4-1.9) 







cum 1169     













21 (0.16) 96 (0.09) 





cum 1167   



















11 (0.09) 45 (0.04) 
















98 (0.77) 623 (0.59) 
      
Other 
Tumors 






23 (0.19) 123 (0.12) 
      
MC1R  score 
0-4 
754 
      
0.008 0.9308 





 63 (0.74) 477 (0.71)       
Abbreviations. N= number of patients, CI= confidence interval, T= Wilcoxon test statistic, H= Kruskal-Wallis test statistic, p= p-value, IQR= interquartile 





Table 5.  
Relative frequencies of CDKN2A pathogenic variants among patients with single and multiple 
melanomas  
N. of melanomas MUT+ MUT-  Row Total 







         







        







         







        
Column Total  129  1056 
 
 1185* 
  (0.109)  (0.891)    
Absolute number of patients is shown outside brackets. Row frequencies are reported on the right, 
whereas column frequencies are reported at the bottom of each cell. 
*Two patients were removed due to missing information on multiple melanomas 
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Table 6. 
Clinical and molecular characteristics of patients selected for survival analysis   




T H p 





58 (0.55) 104 (0.52) 
      
Age median 
(IQR) 
305 43 (32.25-55.5) 44 (33-56) 




Stage IS 305 5 (0.02) 22 (0.05) 
    
1.27 0.26  
Ia-Ib 
 
70 (0.27) 122 (0.27) 





19 (0.07) 37 (0.08) 





7 (0.03) 15 (0.03) 




5 (0.02) 3 (0.01) 
      
Familial Status fam 305 63 (0.5) 0 (0) 




43 (0.34) 199 (1) 
      
N. of Melanomas  cum 305     









44 (0.42) 21 (0.11) 
      
Breslow median 
(IQR) 
305 0.9 (0.36-1.7) 0.9 (0.44-1.7) 




N. of Dysplastic 
Nevi  
cum 299     




N. of Dysplastic 
Nevi  






19 (0.18) 17 (0.09) 
      
N. of Dysplastic 
Nevi After 
Inclusion  
cum 299   




N. of Dysplastic 
Nevi After 
Inclusion  






11 (0.1) 7 (0.04) 
      
Other Skin Lesions  cum 303 















83 (0.78) 142 (0.72) 
      





17 (0.17) 17 (0.09) 
      
MC1R  score 0-4 221 
      
0.1309 0.718 
MC1R  WT 221 19 (0.25) 38 (0.26) 1.04 0.53 2.09 
  
1 
 any r/R  56 (0.75) 108 (0.74)       
Abbreviations. N= number of patients, CI= confidence interval, T= Wilcoxon test statistic, H= Kruskal-Wallis test statistic, p= p-value, IQR= interquartile range, IS= melanoma 







Figure 7. Overall survival and melanoma-specific survival in MUT+ and MUT- melanoma patients 
The Kaplan–Meier curves show similar overall survival (a) and melanoma-specific survival (b) in MUT+ and MUT- patients. 





Figure 8. Overall survival and melanoma-specific survival in MUT+ and MUT- incident-only subset of melanoma patients 
CDKN2A mutational status did not modify overall survival (a) and melanoma-specific survival (b) in incident cutaneous melanoma patients, 
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